The evidence supporting an association of Chlamydia pneumoniae and atherosclerotic cardiovascular disease has prompted interest in assessment of the potential effect of treatment with antibiotics active against the organism on the occurrence of cardiovascular disease outcomes. Results from three small prospective clinical trials have been published [1] [2] [3] and several large secondary prevention trials are currently underway (Dunne MW and Jackson LA, elsewhere this supplement). To evaluate whether past use of antibiotics active against C. pneumoniae is associated with a decrease in the risk of first myocardial infarction (MI), we conducted a population-based casecontrol study of patients enrolled at Group Health Cooperative of Puget Sound (GH) [4] .
Cases diagnosed with an incident fatal or nonfatal MI during July 1986 through December 1995 were frequency-matched with controls from the GH population by methods previously described [5] [6] [7] . The GH computerized pharmacy database, which contains records of all prescriptions dispensed at GH pharmacies, was used to assess prescriptions for erythromycin, tetracycline, and doxycycline for 5 years prior to the date of the MI, for cases, or a comparable index date, for controls. This database contains information on the amount of drug prescribed; to determine duration of use for each agent, we defined 1 day of use as equivalent to 2 g of erythromycin, 2 g of tetracycline, or 100 mg of doxycycline. The total duration of therapy with these drugs was calculated using the sum of the quantities dispensed during the 5 years before the index date.
Characteristics of cases and controls are shown in table 1. In multivariate logistic regression models, there was no significant association or trend toward an association between the duration of prescribed treatment with erythromycin, tetracycline, doxycycline, or the three agents combined, with the risk of incident MI (table 2) . Further, no association was detected when assessment of the use of antibiotics was restricted to a period of 1 year prior to the index date or to nonsmokers (data not shown).
There are several possible explanations for these findings. Treatment with antibiotics active against C. pneumoniae may not affect the risk of cardiac outcomes, either because C. pneumoniae does not play a causal role in the atherosclerotic process or because its effect on that process cannot be modified by antibiotics. Alternatively, treatment with anti-chlamydial antibiotics may be associated with a protective effect, but this effect may vary depending on the specific agent; the dose, duration, or timing of treatment; or the patient's clinical status.
Newer macrolide-like agents, such as azithromycin, are highly active against C. pneumoniae in vitro, achieve much higher intracellular levels and in particular much higher levels in macrophages than do erythromycin, doxycycline, or tetracycline and also have significantly longer half-lives than those agents [8] . It is therefore possible that a true cardiovascular protective effect associated with certain antibiotics active against C. pneumoniae may not be seen with others due either to pharmacodynamic differences or to differences in the mechanisms of action of those agents. Because azithromycin and clarithromycin were not commonly used at GH during the study period, we were unable to include them in our analysis. In addition, among our study population, the cumulative duration of treatment with the antibiotics assessed was relatively limited; only 9% of all subjects had been prescribed у28 days of treatment in total with the three antibiotics combined over the 5-year study period. Thus, the magnitude of exposure to antibiotics in routine clinical care may be insufficient to result in a reduction in risk.
A protective effect of antibiotic treatment may also be limited to the secondary, but not primary, prevention setting, or to patients in the high-risk period following an acute event or to subsets of patients defined by factors that we could not evaluate, such as seropositivity to C. pneumoniae. Further, if the organism plays a role during the initiation or early progression of atherosclerotic lesions, but not in later stages, treatment of older adults may be ineffective. Lastly, while it is possible that our study may have failed to detect a true beneficial effect of past antibiotic treatment, our sample size was relatively large. Assuming a prevalence of exposure among the control group of 42%, this sample size had 90% power (at a 95% confidence interval [CI] ) to detect a 20% reduction in risk associated with antibiotic use.
Our results differ from those of another retrospective casecontrol study of patients with first-time myocardial infarction identified from the United Kingdom (UK)-based General Practice Research Database [9] Although our study and the UK study were similar, it is possible that differences in the populations assessed or in study designs may in part account for the variation in results. Meier and colleagues restricted the case population to persons without other known cardiovascular risk factors such as diabetes or hypertension (although smokers were included); these groups comprised a substantial proportion of the GH study population. Although analyses stratified by risk group did not indicate a trend toward an association, it is possible that the subgroup sizes were too small to demonstrate an effect. The UK study also categorized antibiotic use on the basis of exclusive use of a particular antibiotic class during the study period, while the GH study classified antibiotic use on the basis of any use during the study period regardless of the pattern of other antibiotic use.
In summary, our results suggest that treatment with erythromycin, tetracycline, and doxycycline in doses commonly prescribed in routine clinical practice is not associated with a reduction in the risk of incident MI among our study population.
